Diving to the foot of an iceberg: The SEARCH for undiagnosed atrial fibrillation

 

Editorial Focus on Lowres et al. Thromb Haemost 2014; 111: 1167-1176.

• References

• 1 Heeringa J, van der Kuip DA, Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-953.
• 2 Ball J, Carrington MJ, McMurray JJ, Stewart S. At-rial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013; 167: 1807-1824.
• 3 Chugh SS, Blackshear JL, Shen WK. et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-378.
• 4 Gattellari M, Goumas C, Aitken R, Worthington JM. Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM study (A Program of Research Informing Stroke Management). Cerebrovasc Dis 2011; 32: 370-382.
• 5 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
• 6 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-nalysis of randomised trials. Lancet 2014; 383: 955-962.
• 7 Banerjee A, Lane DA, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabi-gatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
• 8 Skjoth F, Larsen TB, Rasmussen LH. et al. Efficacy and safety of edoxaban in comparison with dabi-gatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111: 981-988.
• 9 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
• 10 Skanes AC, Healey JS, Cairns JA. et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125-136.
• 11 January CT, Wann LS, Alpert JS. et al. 2014 AHA/ ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Epub ahead of print
• 12 Kirchhof P, Breithardt G, Camm AJ. et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of At-rial fibrillation for Stroke prevention Trial. Am Heart J 2013; 166: 442-448.
• 13 Levy S, Maarek M, Coumel P. et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFAstudy The College of French Cardiologists. Circulation 1999; 99: 3028-3035.
• 14 Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 2013; 168: 4744-4749.
• 15 Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation A systematic review. Thromb Haemost 2013; 110: 213-222.
• 16 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683-685.
• 17 Keogh C, Wallace E, Dillon C. et al. Validation of the CHADS2 clinical prediction rule to predict is-chaemic stroke A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538.
• 18 Elijovich L, Josephson SA, Fung GL, Smith WS. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis 2009; 18: 185-189.
• 19 Sudlow M, Rodgers H, Kenny RA, Thomson R. Identification of patients with atrial fibrillation in general practice: a study of screening methods. Br Med J 1998; 317: 327-328.
• 20 Baxter J, Crabtree L, Hildreth A. et al. Atrial fibrillation. Lancet 1998; 352: 1858.
• 21 Wheeldon NM, Tayler DI, Anagnostou E. et al. Screening for atrial fibrillation in primary care. Heart 1998; 79: 50-55.
• 22 Lowres N, Neubeck L, Salkeld G. et al. Feasibility cost effectiveness of stroke prevention through community screening for AF using iPhone ECG in pharmacies The SEARCH-AF study. Thromb Haemost 2014; 111: 1167-1176.
• 23 Moran PS, Flattery MJ, Teljeur C. et al. Effectiveness of systematic screening for the detection of at-rial fibrillation. Cochrane Datab System Rev 2013; 04: CD009586.
• 24 Mant J, Fitzmaurice DA, Hobbs FD. et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. Br Med J 2007; 335: 380.
• 25 Lewis M, Parker D, Weston C, Bowes M. Screening for atrial fibrillation: sensitivity and specificity of a new methodology. Br J General Pract 2011; 61: 38-39.
• 26 Wiesel J, Fitzig L, Herschman Y, Messineo FC. Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hyperten 2009; 22: 848-852.
• 27 McManus DD, Lee J, Maitas O. et al. A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm 2013; 10: 315-319.
• 28 Hobbs FD, Fitzmaurice DA, Mant J. et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005; 09 iii-iv, ix-x 1-74.
• 29 Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013; 127: 930-937.
• 30 Ziegler PD, Glotzer TV, Daoud EG. et al. Incidence of newly detected atrial arrhythmias via implant-able devices in patients with a history of throm-boembolic events. Stroke 2010; 41: 256-260.
• 31 Glotzer TV, Daoud EG, Wyse DG. et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circulation Ar-rhythm Electrophysiol 2009; 02: 474-480.
• 32 Glotzer TV, Hellkamp AS, Zimmerman J. et al. At-rial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003; 107: 1614-1619.
• 33 Healey JS, Connolly SJ, Gold MR. et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366: 120-129.
• 34 Lahaye S, Regpala S, Lacombe S. et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465-473.
• 35 Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783-788.
• 36 Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost 2014; 111: 808-816.
• 37 Marinigh R, Lip GY, Fiotti N. et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Car-diol 2010; 56: 827-837.